Choksi Laboratories Ltd
Incorporated in 1982, Choksi Laboratories Ltd provides contract testing and analytical services. Company analyzes for its clients, or as a regulatory requirement in industries such as pharmaceutical, food, engineering and
construction material.
- Market Cap ₹ 122 Cr.
- Current Price ₹ 176
- High / Low ₹ 176 / 51.8
- Stock P/E 80.5
- Book Value ₹ 33.9
- Dividend Yield 0.00 %
- ROCE 9.13 %
- ROE 6.63 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 66.7 days to 43.9 days
Cons
- Stock is trading at 5.18 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.21% over past five years.
- Promoter holding is low: 31.5%
- Company has a low return on equity of 6.66% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
22.16 | 24.45 | 25.10 | 28.63 | 30.40 | 33.74 | 28.16 | 25.69 | 30.04 | 34.44 | 36.70 | 41.78 | |
17.85 | 19.30 | 19.95 | 23.85 | 24.06 | 26.48 | 24.62 | 21.57 | 21.14 | 24.17 | 26.42 | 30.55 | |
Operating Profit | 4.31 | 5.15 | 5.15 | 4.78 | 6.34 | 7.26 | 3.54 | 4.12 | 8.90 | 10.27 | 10.28 | 11.23 |
OPM % | 19.45% | 21.06% | 20.52% | 16.70% | 20.86% | 21.52% | 12.57% | 16.04% | 29.63% | 29.82% | 28.01% | 26.88% |
0.10 | 0.63 | -0.05 | 0.86 | 0.35 | 0.25 | -2.80 | 0.49 | 0.12 | 2.47 | 0.16 | 0.07 | |
Interest | 1.19 | 1.57 | 1.23 | 1.47 | 1.59 | 1.54 | 1.89 | 2.82 | 3.23 | 3.52 | 3.06 | 2.65 |
Depreciation | 1.59 | 2.83 | 2.73 | 2.86 | 3.16 | 3.68 | 4.56 | 4.60 | 5.43 | 5.50 | 5.71 | 6.50 |
Profit before tax | 1.63 | 1.38 | 1.14 | 1.31 | 1.94 | 2.29 | -5.71 | -2.81 | 0.36 | 3.72 | 1.67 | 2.15 |
Tax % | 28.83% | 36.23% | 36.84% | 32.06% | 29.90% | 30.13% | -32.05% | -7.12% | 44.44% | 13.71% | 32.93% | 29.30% |
1.17 | 0.88 | 0.72 | 0.89 | 1.35 | 1.60 | -3.88 | -2.61 | 0.21 | 3.21 | 1.11 | 1.52 | |
EPS in Rs | 1.68 | 1.26 | 1.03 | 1.28 | 1.94 | 2.30 | -5.57 | -3.75 | 0.30 | 4.61 | 1.59 | 2.18 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 8% |
3 Years: | 12% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 32% |
3 Years: | 93% |
TTM: | 37% |
Stock Price CAGR | |
---|---|
10 Years: | 35% |
5 Years: | 79% |
3 Years: | 73% |
1 Year: | 218% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 2% |
3 Years: | 7% |
Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
Reserves | 13.35 | 12.35 | 13.07 | 14.16 | 15.43 | 17.04 | 13.26 | 10.78 | 10.94 | 14.14 | 15.25 | 16.64 |
11.45 | 11.65 | 13.68 | 11.20 | 12.43 | 17.05 | 31.64 | 39.15 | 37.29 | 32.41 | 30.87 | 28.42 | |
6.93 | 6.70 | 8.81 | 8.32 | 9.85 | 14.28 | 13.14 | 9.48 | 9.22 | 6.84 | 8.86 | 13.30 | |
Total Liabilities | 38.70 | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 |
23.98 | 19.28 | 17.64 | 22.23 | 28.62 | 34.81 | 33.08 | 50.32 | 46.56 | 44.83 | 43.43 | 47.61 | |
CWIP | 2.23 | 2.73 | 8.99 | 4.28 | 0.00 | 3.23 | 13.06 | 0.50 | 1.67 | 0.31 | 2.99 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
12.49 | 15.66 | 15.90 | 14.14 | 16.06 | 17.30 | 18.87 | 15.56 | 16.19 | 15.22 | 15.53 | 17.72 | |
Total Assets | 38.70 | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3.77 | 2.30 | 0.01 | 6.57 | 6.25 | 6.91 | 2.87 | 5.90 | 7.88 | 8.25 | 11.55 | ||
-6.10 | -0.73 | -0.01 | -1.88 | -4.92 | -9.76 | -13.76 | -7.65 | -2.71 | -0.71 | -6.65 | ||
1.31 | -1.37 | 0.00 | -4.89 | -0.94 | 2.13 | 11.09 | 1.63 | -5.07 | -7.61 | -4.58 | ||
Net Cash Flow | -1.02 | 0.21 | 0.00 | -0.20 | 0.39 | -0.72 | 0.20 | -0.12 | 0.10 | -0.07 | 0.32 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 117.27 | 126.15 | 124.77 | 112.19 | 118.62 | 95.09 | 90.60 | 115.94 | 125.03 | 112.87 | 103.33 | 98.46 |
Inventory Days | 0.00 | 0.00 | 0.00 | 28.27 | 30.50 | 37.89 | 20.28 | 15.62 | 46.09 | 34.68 | 51.33 | 65.94 |
Days Payable | 591.13 | 594.31 | 660.70 | 723.24 | 685.97 | 741.06 | 297.29 | 560.33 | 639.34 | |||
Cash Conversion Cycle | 117.27 | 126.15 | 124.77 | -450.67 | -445.18 | -527.72 | -612.36 | -554.41 | -569.95 | -149.73 | -405.67 | -474.95 |
Working Capital Days | 52.71 | 73.45 | 44.35 | 24.22 | 33.74 | 40.13 | 53.40 | 61.09 | 70.11 | 88.07 | 68.23 | 43.86 |
ROCE % | 9.25% | 7.94% | 7.51% | 7.33% | 10.51% | 10.09% | -1.48% | 0.00% | 6.40% | 9.16% | 8.87% | 9.13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Extract of Audited Financial Results for the quarter and financial year ended 31st March, 2025 has been published in the newspaper
- Financial Result For Quarter And Year Ended 31.03.2025 7 Jun
-
Board Meeting Outcome for Outcome Of Board Meeting Dated 07Th June, 2025
7 Jun - Audited FY25 results approved; disclosed May 2025 ransomware attack causing temporary disruption.
-
Board Meeting Intimation for Meeting Of Board To Be Held On 07.06.2025
31 May - Board meeting on June 7 to approve FY25 audited results after cyber-attack delay.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Choksi Laboratories submits Annual Secretarial Compliance Report for FY ended March 31, 2025; no non-compliances noted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered:[1]
a) Contract Laboratory Services (CLS):[2]
Company provides four different analysis under CLS, viz.
Pharmaceutical Analysis
Food & Beverages Analysis
Water Analysis
Construction Material Analysis
b) Instrument Calibration & Validation Services:[3] Company provides Laboratory and On-Site calibration for test equipment, process equipment, and in many cases end-user equipment, Plant Shutdown Calibration, and consultancy for setting up an in-house calibration laboratory.
c) Environmental Management Services:[4]
Company helps industries develop their Waste Disposal and Effluent Treatment capabilities along with Air Pollution Monitoring, and Waste Water Management
d) Clinical Research Services:[5]
Company has developed a 40-bed clinical research facility for carrying out Bio-Availability and Bio-Equivalence studies
e) Consultancy:[6]
Company provides Training, Auditing, and Consultancy for organizations
f) Assaying & Hallmarking:[7]
Company has set up a gold & silver hallmarking center with EDXRF, Laser assisted marking machine and fire-assay facilities.